Interaction between antiretroviral therapy regimens and body mass index on triglyceride levels in people living with HIV: a cross-sectional and longitudinal study

• Published in: Lipids in health and disease 2024-07, Vol.23 (1), p.232-10, Article 232
• Main Authors: Xu, Yide, Qi, Bufeng, Wu, Xiaolu, Lu, Chen, Chen, Pei, Wang, Dongdong, Li, Xiaoting, Xie, Chunfeng, Wu, Jieshu, Zhong, Caiyun, Li, Lin, Gao, Gu, Yang, Dandan, Ding, Ye, Geng, Shanshan
• Format: Article
• Language: English
• Subjects: Adult; Analysis; Anti-HIV Agents - therapeutic use; Antiretroviral therapy; Antiretroviral Therapy, Highly Active; Body Mass Index; Cross-Sectional Studies; Development and progression; Efavirenz; Highly active antiretroviral therapy; HIV (Viruses); HIV Infections - blood; HIV Infections - drug therapy; HIV patients; Humans; Hypertriglyceridemia - blood; Interaction; Longitudinal Studies; Male; Middle Aged; Proteases; Triglyceride; Triglycerides; Triglycerides - blood; Waist-Hip Ratio; Zidovudine; Zidovudine - therapeutic use
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-024-02224-8

To investigate how antiretroviral therapy (ART) regimens and body mass index (BMI) interact to affect triglyceride (TG) levels in people living with HIV (PLWH). This research involved 451 men living with HIV for cross-sectional analysis, and 132 underwent follow-up assessments in 2021 and 2023. Multivariate logistic regression identified key factors, while covariance regression models assessed interactions between ART regimens and BMI on TG levels. The result of this cross-sectional study indicated that advanced AIDS (acquired immune deficiency syndrome) stage (OR = 2.756, P = 0.003), higher BMI (OR = 1.131, P = 0.003), and waist-hip ratio (WHR, OR = 44.684, P = 0.019) are closely associated with high triglyceride levels. Additionally, regimens containing zidovudine (AZT) (OR = 3.927, P